NASDAQ:RANI Rani Therapeutics (RANI) Stock Forecast, Price & News $4.19 +0.08 (+1.95%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$4.10▼$4.3550-Day Range$3.92▼$6.3352-Week Range$3.65▼$13.44Volume90,086 shsAverage Volume82,710 shsMarket Capitalization$207.36 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Rani Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside448.9% Upside$23.00 Price TargetShort InterestBearish4.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 3 Articles This WeekInsider TradingAcquiring Shares$334,923 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.44) to ($1.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector700th out of 1,012 stocksPharmaceutical Preparations Industry352nd out of 495 stocks 3.5 Analyst's Opinion Consensus RatingRani Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.00, Rani Therapeutics has a forecasted upside of 448.9% from its current price of $4.19.Amount of Analyst CoverageRani Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.28% of the float of Rani Therapeutics has been sold short.Short Interest Ratio / Days to CoverRani Therapeutics has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in Rani Therapeutics has recently increased by 18.31%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRani Therapeutics does not currently pay a dividend.Dividend GrowthRani Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RANI. Previous Next 2.6 News and Social Media Coverage News SentimentRani Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Rani Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for RANI on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows3 people have added Rani Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rani Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $334,923.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders50.02% of the stock of Rani Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.43% of the stock of Rani Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Rani Therapeutics are expected to decrease in the coming year, from ($1.44) to ($1.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rani Therapeutics is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rani Therapeutics is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRani Therapeutics has a P/B Ratio of 3.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Rani Therapeutics (NASDAQ:RANI) StockRani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.Read More Receive RANI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RANI Stock News HeadlinesMay 24, 2023 | finance.yahoo.comRani Therapeutics Appoints Kate McKinley as Chief Business OfficerMay 17, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Issued By HC WainwrightMay 28, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 16, 2023 | americanbankingnews.comWedbush Analysts Lift Earnings Estimates for Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)May 12, 2023 | americanbankingnews.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Major Shareholder Acquires $19,713.20 in StockMay 11, 2023 | msn.comHC Wainwright & Co. Reiterates Rani Therapeutics Holdings Inc (RANI) Buy RecommendationMay 10, 2023 | benzinga.comRani Therapeutics Hldgs: Q1 Earnings InsightsMay 10, 2023 | finance.yahoo.comRani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate UpdateMay 28, 2023 | Stocks To Trade (Ad)3 Free Stock Picks per DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Repare Therapeutics (RPTX) and ARS Pharmaceuticals (SPRY)May 4, 2023 | americanbankingnews.comSouth Cone Investments Limited Purchases 2,173 Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) StockApril 27, 2023 | americanbankingnews.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Major Shareholder South Cone Investments Limited Buys 4,280 SharesApril 26, 2023 | finance.yahoo.comRani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) last week's 14% decline must have disappointed private companies who have a significant stakeApril 25, 2023 | finance.yahoo.comRani Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQApril 21, 2023 | americanbankingnews.comRani Therapeutics (NASDAQ:RANI) Receives New Coverage from Analysts at BTIG ResearchApril 19, 2023 | americanbankingnews.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Major Shareholder South Cone Investments Limited Purchases 1,901 SharesApril 17, 2023 | msn.comInsiders Buying Rani Therapeutics And 1 Other StockApril 15, 2023 | americanbankingnews.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Major Shareholder South Cone Investments Limited Purchases 3,577 SharesApril 11, 2023 | finance.yahoo.comRani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare ConferenceApril 8, 2023 | americanbankingnews.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Major Shareholder South Cone Investments Limited Purchases 7,280 SharesApril 7, 2023 | americanbankingnews.comSouth Cone Investments Limited Purchases 3,587 Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) StockApril 6, 2023 | marketwatch.com8-K: Rani Therapeutics Holdings, Inc.April 6, 2023 | americanbankingnews.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Major Shareholder Buys $58,581.70 in StockApril 1, 2023 | americanbankingnews.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Major Shareholder Buys $19,269.90 in StockMarch 28, 2023 | americanbankingnews.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) to Post Q1 2023 Earnings of ($0.79) Per Share, HC Wainwright ForecastsMarch 27, 2023 | finance.yahoo.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2022 Earnings Call TranscriptMarch 24, 2023 | americanbankingnews.comRani Therapeutics (NASDAQ:RANI) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPSSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RANI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RANI Company Calendar Last Earnings3/22/2023Today5/28/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RANI CUSIPN/A CIK1856725 Webwww.ranitherapeutics.com Phone408-457-3700FaxN/AEmployees114Year FoundedN/APrice Target and Rating Average Stock Price Forecast$23.00 High Stock Price Forecast$24.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+448.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-40.81% Return on Assets-31.40% Debt Debt-to-Equity Ratio0.47 Current Ratio17.29 Quick Ratio17.29 Sales & Book Value Annual Sales$2.72 million Price / Sales76.24 Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book3.38Miscellaneous Outstanding Shares49,490,000Free Float24,737,000Market Cap$207.36 million OptionableNot Optionable Beta0.33 Key ExecutivesMr. Mir A. Imran (Age 66)Exec. Chairman Comp: $33.33kMr. Talat Imran (Age 41)CEO & Director Comp: $1.07MMr. Svai S. Sanford (Age 52)Chief Financial Officer Comp: $675.74kDr. Mir Hashim (Age 62)Chief Scientific Officer Comp: $696.92kMr. Eric GroenGen. CounselMs. Bella VazquezVP of HRMore ExecutivesKey CompetitorsAltimmuneNASDAQ:ALTCorMedixNASDAQ:CRMDKezar Life SciencesNASDAQ:KZRNkartaNASDAQ:NKTXNature's Sunshine ProductsNASDAQ:NATRView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPBought 70,772 shares on 5/16/2023Ownership: 0.143%Renaissance Technologies LLCBought 2,717 shares on 5/12/2023Ownership: 0.083%HRT Financial LPBought 18,098 shares on 5/12/2023Ownership: 0.037%Bank of America Corp DEBought 9,618 shares on 5/12/2023Ownership: 0.027%South Cone Investments LimitedBought 2,610 shares on 5/11/2023Total: $10,100.70 ($3.87/share)View All Insider TransactionsView All Institutional Transactions RANI Stock - Frequently Asked Questions Should I buy or sell Rani Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rani Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RANI shares. View RANI analyst ratings or view top-rated stocks. What is Rani Therapeutics' stock price forecast for 2023? 4 brokers have issued 1-year price objectives for Rani Therapeutics' shares. Their RANI share price forecasts range from $22.00 to $24.00. On average, they predict the company's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 448.9% from the stock's current price. View analysts price targets for RANI or view top-rated stocks among Wall Street analysts. How have RANI shares performed in 2023? Rani Therapeutics' stock was trading at $5.90 at the beginning of the year. Since then, RANI stock has decreased by 29.0% and is now trading at $4.19. View the best growth stocks for 2023 here. Are investors shorting Rani Therapeutics? Rani Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 724,900 shares, an increase of 18.3% from the April 30th total of 612,700 shares. Based on an average daily volume of 53,200 shares, the short-interest ratio is presently 13.6 days. Currently, 4.3% of the company's stock are short sold. View Rani Therapeutics' Short Interest. When is Rani Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our RANI earnings forecast. How were Rani Therapeutics' earnings last quarter? Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) issued its quarterly earnings data on Wednesday, March, 22nd. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.01. During the same period in the previous year, the business posted ($0.27) earnings per share. When did Rani Therapeutics IPO? (RANI) raised $100 million in an IPO on Friday, July 30th 2021. The company issued 6,666,667 shares at $14.00-$16.00 per share. What is Rani Therapeutics' stock symbol? Rani Therapeutics trades on the NASDAQ under the ticker symbol "RANI." Who are Rani Therapeutics' major shareholders? Rani Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Alphabet Inc. (0.91%), Susquehanna International Group LLP (0.14%), Renaissance Technologies LLC (0.08%), HRT Financial LP (0.04%), Bank of America Corp DE (0.03%) and Icon Wealth Partners LLC (0.03%). Insiders that own company stock include Cortes Isidoro Alfonso Quiroga, Mir A Imran and South Cone Investments Limited. View institutional ownership trends. How do I buy shares of Rani Therapeutics? Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Rani Therapeutics' stock price today? One share of RANI stock can currently be purchased for approximately $4.19. How much money does Rani Therapeutics make? Rani Therapeutics (NASDAQ:RANI) has a market capitalization of $207.36 million and generates $2.72 million in revenue each year. The company earns $-30,590,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. How many employees does Rani Therapeutics have? The company employs 114 workers across the globe. How can I contact Rani Therapeutics? The official website for the company is www.ranitherapeutics.com. The company can be reached via phone at 408-457-3700 or via email at ir@ranitherapeutics.com. This page (NASDAQ:RANI) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.